AAAAAA

   
Results: 1-22 |
Results: 22
Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment
Authors: Rozenbaum, W Katlama, C Massip, P Bentata, M Zucman, D Delfraissy, JF Trepo, C David, F Lanier, ER Vavro, C Mamet, JP
Citation: W. Rozenbaum et al., Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment, ANTIVIR TH, 6(2), 2001, pp. 135-142
Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection
Authors: Girard, PM Schneider, V Dehee, A Mariot, P Jacomet, C Delphin, N Damond, F Carcelain, G Autran, B Saimot, AG Nicolas, JC Rozenbaum, W
Citation: Pm. Girard et al., Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection, AIDS, 15(2), 2001, pp. 275-277
Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA
Authors: Clumeck, N Goebel, F Rozenbaum, W Gerstoft, J Staszewski, S Montaner, J Johnson, M Gazzard, B Stone, C Athisegaran, R Moore, S
Citation: N. Clumeck et al., Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA, AIDS, 15(12), 2001, pp. 1517-1526
Quantification of Epstein-Barr virus load in peripheral blood of human immunodeficiency virus-infected patients using real-time PCR
Authors: Dehee, A Asselot, C Piolot, T Jacomet, C Rozenbaum, W Vidaud, M Garbarg-Chenon, A Nicolas, JC
Citation: A. Dehee et al., Quantification of Epstein-Barr virus load in peripheral blood of human immunodeficiency virus-infected patients using real-time PCR, J MED VIROL, 65(3), 2001, pp. 543-552
Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay
Authors: Desire, N Dehee, A Schneider, V Jacomet, C Goujon, C Girard, PM Rozenbaum, W Nicolas, JC
Citation: N. Desire et al., Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay, J CLIN MICR, 39(4), 2001, pp. 1303-1310
Reversible ALS-like disorder in HIV infection
Authors: Moulignier, A Moulonguet, A Pialoux, G Rozenbaum, W
Citation: A. Moulignier et al., Reversible ALS-like disorder in HIV infection, NEUROLOGY, 57(6), 2001, pp. 995-1001
Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy
Authors: Besson, C Goubar, A Gabarre, J Rozenbaum, W Pialoux, G Chatelet, FP Katlama, C Charlotte, F Dupont, B Brousse, N Huerre, M Mikol, J Camparo, P Mokhtari, K Tulliez, M Salmon-Ceron, D Boue, F Costagliola, D Raphael, M
Citation: C. Besson et al., Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy, BLOOD, 98(8), 2001, pp. 2339-2344
The VIRGO Study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults
Authors: Raffi, F Reliquet, V Ferre, V Arvieux, C Hascoet, C Bellein, V Besnier, JM Breuz, JP Garre, M May, T Molina, JM Perre, P Raguin, G Rozenbaum, W Zucman, D
Citation: F. Raffi et al., The VIRGO Study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults, ANTIVIR TH, 5(4), 2000, pp. 267-272
Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens
Authors: Girard, PM Guiguet, M Bollens, D Goderel, I Meyohas, MC Lecomte, I Raguin, G Frottier, J Rozenbaum, W Jaillon, P
Citation: Pm. Girard et al., Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens, CLIN INF D, 31(4), 2000, pp. 987-994
Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients
Authors: Dubreuil-Lemaire, ML Gori, A Vittecoq, D Panelatti, G Tharaux, F Palisses, R Gharakhanian, S Rozenbaum, W
Citation: Ml. Dubreuil-lemaire et al., Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients, EUR J HAEMA, 65(5), 2000, pp. 337-343
Piercing and infectious complications: an important public health issue inFrance
Authors: Guiard-Schmid, JB Picard, H Slama, L Maslo, C Amiel, C Pialoux, G Lebrette, MG Rozenbaum, W
Citation: Jb. Guiard-schmid et al., Piercing and infectious complications: an important public health issue inFrance, PRESSE MED, 29(35), 2000, pp. 1948-1956
AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients
Authors: Gartland, M Gerstoft, J Goebel, F Clumeck, N Cooper, DA Gatell, J Gazzard, B Gerstoft, J Goebel, F Lange, J Montaner, J Reiss, P Rozenbaum, W Vella, S Beveridge, A Cooper, DA Duncombe, C Gold, J Haberl, M Clumeck, N Luyts, D Montaner, J Rachlis, A Marina, R Gerstoft, J Wandall, JH Elbrond, B Molina, JM Pialloux, G Rozenbaum, W Beauvais, L Goebel, FD Staszewski, S Bruns, I Hug, M Reiss, P Lange, J Frissen, PHJ van der Ende, ME Bosboom, M Baas, C Milazzo, F Moroni, M Panebianco, R Clotet, B Artigas, JMG Gonzalez-Lahoz, J Leal, M Rodriguez-Lopo, C Gandarias, B Gazzard, B Johnson, M McKinley, S Page, V Watkins, K Sandstrom, E Belsey, E Darbyshire, J Chodakewitz, J Isaacs, R Jonas, L Meibohm, A Coughlan, M Fiddian, P Gartland, M Harrigan, R Larder, B Maguire, M Millard, J Moore, S Patel, K Shortino, D Tisdale, M Vafidis, I Yeo, J
Citation: M. Gartland et al., AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients, AIDS, 14(4), 2000, pp. 367-374
Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit
Authors: Reiss, P Vella, S Cooper, D Lange, J Gartland, M Gerstoft, J Goebel, F Larder, B Clumeck, N Gatell, J Gazzard, B Rozenbaum, W Rae, S O'Shaughnessy, MV Robinson, P Harrigan, PR Raboud, J Alexander, CS Maguire, M Montaner, JS
Citation: P. Reiss et al., Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit, AIDS, 14(10), 2000, pp. 1383-1388
Quantitative analysis of human herpesvirus 8 viral load using a real-time PCR assay
Authors: Lallemand, F Desire, N Rozenbaum, W Nicolas, JC Marechal, V
Citation: F. Lallemand et al., Quantitative analysis of human herpesvirus 8 viral load using a real-time PCR assay, J CLIN MICR, 38(4), 2000, pp. 1404-1408
Phylogenetic analyses indicate an atypical nurse-to-patient transmission of human immunodeficiency virus type 1
Authors: Goujon, CP Schneider, VM Grofti, J Montigny, J Jeantils, V Astagneau, P Rozenbaum, W Lot, F Frocrain-Herchkovitch, C Delphin, N Le Gal, F Nicolas, JC Milinkovitch, MC Deny, P
Citation: Cp. Goujon et al., Phylogenetic analyses indicate an atypical nurse-to-patient transmission of human immunodeficiency virus type 1, J VIROLOGY, 74(6), 2000, pp. 2525-2532
Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients
Authors: Molina, JM Ferchal, F Rancinan, C Raffi, F Rozenbaum, W Sereni, D Morlat, P Journot, V Decazes, JM Chene, G
Citation: Jm. Molina et al., Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients, J INFEC DIS, 182(2), 2000, pp. 599-602
Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients
Authors: Reliquet, V Ferre, V Hascoet, C Besnier, JM Bellein, V Arvieux, C Molina, JM Breux, JP Zucman, D Rozenbaum, W Allavena, C Raffi, F
Citation: V. Reliquet et al., Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients, ANTIVIR TH, 4, 1999, pp. 83-84
Adverse metabolic disorders during highly active antiretroviral treatments(HAART) of HIV disease
Authors: Vigouroux, C Gharakhanian, S Salhi, Y Nguyen, TH Adda, N Rozenbaum, W Capeau, J
Citation: C. Vigouroux et al., Adverse metabolic disorders during highly active antiretroviral treatments(HAART) of HIV disease, DIABETE MET, 25(5), 1999, pp. 383-392
Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART)
Authors: Vigouroux, C Gharakhanian, S Salhi, Y Nguyen, TH Chevenne, D Capeau, J Rozenbaum, W
Citation: C. Vigouroux et al., Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART), DIABETE MET, 25(3), 1999, pp. 225-232
Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination
Authors: Lallemand, F Adda, N Schneider, V Jacomet, C Salhi, Y Rozenbaum, W
Citation: F. Lallemand et al., Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination, CLIN INF D, 28(5), 1999, pp. 1184-1185
Analysis of HIV-1 clinical trials: statistical magic?
Authors: Cooper, D Clumeck, N Montaner, J Harrigan, R Gerstoft, J Rozenbaum, W Goebel, FD Reiss, P Lange, J Vella, S Artigas, JMG Gazzard, B
Citation: D. Cooper et al., Analysis of HIV-1 clinical trials: statistical magic?, LANCET, 353(9169), 1999, pp. 2061-2064
Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results
Authors: Raffi, F Reliquet, V Francois, C Garre, M Hascoet, C Allavena, C Arvieux, C Breux, JP Perre, P Rozenbaum, W Auger, S
Citation: F. Raffi et al., Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results, ANTIVIR TH, 3, 1998, pp. 57-60
Risultati: 1-22 |